Chemical inhibitors of Skint2 include a variety of compounds that impede the protein's function by targeting different aspects of its regulation and signaling pathways. Haloperidol, a dopamine receptor antagonist, directly blocks dopaminergic signaling pathways that are crucial for Skint2-mediated cellular responses, thereby inhibiting the function of Skint2. Similarly, Losartan interrupts angiotensin II-mediated signaling pathways, which are known to regulate Skint2 activity. This disruption leads to a decrease in Skint2 function by preventing its activation through these pathways. SB203580 and PD98059 both target MAP kinase signaling pathways, with SB203580 inhibiting p38 MAP kinase and PD98059 targeting MAPK/ERK. These pathways are involved in Skint2 regulation, and their inhibition results in a reduction of Skint2 activity. LY294002 and Wortmannin, as PI3K inhibitors, obstruct the PI3K/Akt signaling pathway, which is also involved in the control of Skint2 activity, leading to a decrease in the protein's function.
In addition to these, SP600125, a JNK inhibitor, diminishes Skint2 function by impeding the JNK signaling pathway that modulates Skint2 activity. MG132, by inhibiting the proteasome, prevents the degradation of proteins that regulate Skint2, thus maintaining an increased level of regulatory proteins that can inhibit Skint2 activity. BAPTA-AM, a calcium chelator, sequesters intracellular calcium thereby inhibiting Skint2-dependent signaling pathways and reducing Skint2 function. U73122, by inhibiting phospholipase C, impairs PLC-dependent signaling pathways which are necessary for Skint2 activity. Rapamycin, an mTOR inhibitor, obstructs mTOR signaling pathways that play a role in the regulation of Skint2, leading to its decreased activity. Lastly, GF109203X, as a protein kinase C inhibitor, hinders PKC-dependent pathways necessary for Skint2 function, resulting in decreased Skint2 activity. Each of these chemicals targets specific signaling pathways or cellular processes to inhibit the function of Skint2, demonstrating a direct or indirect mechanism of action that culminates in the inhibition of Skint2.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol, a dopamine receptor antagonist, inhibits Skint2 by blocking dopaminergic signaling which is necessary for Skint2-mediated cellular responses. This inhibition can lead to reduced function of Skint2-dependent pathways. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan, an angiotensin II receptor blocker, can inhibit Skint2 by interfering with angiotensin II-mediated signaling pathways that are known to regulate Skint2 activity, thus indirectly leading to decreased Skint2 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAP kinase inhibitor, inhibits Skint2 by suppressing the MAPK pathway, which is involved in the regulation of Skint2 activity, resulting in decreased function of Skint2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, can inhibit Skint2 by blocking the PI3K/Akt signaling pathway which has a regulatory role on Skint2 activity, thus diminishing Skint2 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, an inhibitor of MAPK/ERK, inhibits Skint2 by impairing the MAPK/ERK signaling pathway which affects Skint2 activity, leading to reduced Skint2 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, can inhibit Skint2 by obstructing the JNK signaling pathway which modulates Skint2 activity, thereby decreasing Skint2 function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132, a proteasome inhibitor, can inhibit Skint2 by preventing the degradation of regulatory proteins that control Skint2 activity, resulting in diminished Skint2 function. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM, a calcium chelator, inhibits Skint2 by sequestering intracellular calcium, which is essential for Skint2-mediated signaling, leading to reduced Skint2 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor like LY294002, inhibits Skint2 by blocking the same PI3K/Akt pathway crucial for Skint2 activity, which leads to decreased Skint2 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, can inhibit Skint2 by obstructing the mTOR signaling pathway that plays a role in Skint2 regulation, leading to reduced Skint2 activity. | ||||||